Chelsie Derman

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

A study shows young adults with negative emotionality, particularly alienation, who experienced childhood adversities often experience more stressful life events in adulthood.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

Patients with schizophrenia and COVID-19 both present dysregulated energy metabolism, explaining the high COVID-19 rates among those with schizophrenia.

Investigators developed and validated a novel model to identify liver fibrosis in patients with diabetes which performed better than existing models.

A new study identifies sex differences in MASLD adverse events, such as females having a greater risk of developing cirrhosis and males having a greater risk of non-liver cancers.

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.

A recent study found that loneliness among adults aged 50 – 80 increased from 2018 to 2022 and dropped in 2023 and 2024.

A recent study examined the phase 3 trials ADVANCE, PROGRESS, and ELEVATE and saw atogepant 60 mg as a preventive migraine treatment improves quality of life and functioning.

A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.

This Month in Review captures November updates in the psychiatry pipeline.

A study found psilocybin therapy brings life-changing relief to depression symptoms triggered by clinicians’ frontline work during the COVID-19 pandemic.

A new study showed patients with MASLD have fragmented nocturnal sleep with frequent awakenings per night and a session on healthy sleep habits did not improve sleep parameters.

A study revealed that people who are older, uneducated, unemployed, below the poverty line, publicly insured, rural, and male did not increase in psychotherapy use from 2018 to 2021.

Intra-Cellular Therapies announced they submitted a supplemental New Drug Application to the FDA for lumateperone (CAPLYTA) as an adjunctive therapy to antidepressants for MDD.

Dreem 3S is the first sleep wearable with an FDA-authorized Predetermined Change Control Plan.

A study found patients with schizophrenia exhibiting violence, vs. those who don’t, have less gray matter volume in the frontal lobe and greater thyroid-stimulating hormone levels.

A new study supports mindfulness-based interventions as a complementary treatment for patients with schizophrenia spectrum disorders.

A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.

A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.

A study identified homelessness and minority status as factors that impact clozapine prescription patterns.

Following the publication of the new RLS recommendations, HCPLive spoke with John Winkelman, MD, PhD, chair of the AASM committee that revised the guidelines.

HCPLive spoke with Kastl at NASPGHAN about the team’s study on the immune response to the COVID-19 vaccination among children with IBD.

At NASPGHAN, HCPLive spoke to Hamant about her team’s study that showed their algorithm was linked to increased VTE Prophylaxis among Pediatric IBD.

Bifidobacterium longum 35624TM reduces IBS symptom severity in children and adolescents, according to a study presented at NASPGHAN 2024.